Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sheaff

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
The Journal of Pathology|June 28, 2011
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancerIan Paul, Kienan I Savage, Jaine K Blayney, et al.
Oncoimmunology|December 7, 2017
CAR T-cell immunotherapy of MET-expressing malignant mesotheliomaThivyan Thayaparan, Roseanna M Petrovic, Daniela Y Achkova, et al.
Molecular Cancer Therapeutics|November 7, 2020
BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in MesotheliomaSara Busacca, Laura O'Regan, Anita Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2017
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic CancersEmma Beddowes, James Spicer, Pui Ying Chan, et al.
Cancer Medicine|August 12, 2021
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancerPeter W Szlosarek, Akhila G Wimalasingham, Melissa M Phillips, et al.
British Journal of Haematology|March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2020
Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation Markers Associated With Progression to CancerRamon P van der Zee, Olivier Richel, Carel J M van Noesel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade GliomaPeter E Hall, Rachel Lewis, Nelofer Syed, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
Archives of Pathology & Laboratory Medicine|April 8, 2024
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest GroupAliya N Husain, David B Chapel, Richard Attanoos, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
The Journal of Pathology|June 28, 2011
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancerIan Paul, Kienan I Savage, Jaine K Blayney, et al.
Oncoimmunology|December 7, 2017
CAR T-cell immunotherapy of MET-expressing malignant mesotheliomaThivyan Thayaparan, Roseanna M Petrovic, Daniela Y Achkova, et al.
Molecular Cancer Therapeutics|November 7, 2020
BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in MesotheliomaSara Busacca, Laura O'Regan, Anita Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2017
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic CancersEmma Beddowes, James Spicer, Pui Ying Chan, et al.
Cancer Medicine|August 12, 2021
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancerPeter W Szlosarek, Akhila G Wimalasingham, Melissa M Phillips, et al.
British Journal of Haematology|March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2020
Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation Markers Associated With Progression to CancerRamon P van der Zee, Olivier Richel, Carel J M van Noesel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade GliomaPeter E Hall, Rachel Lewis, Nelofer Syed, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
Archives of Pathology & Laboratory Medicine|April 8, 2024
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest GroupAliya N Husain, David B Chapel, Richard Attanoos, et al.
Pageof 7